Annual SG&A
$61.17 M
-$1.51 M-2.42%
31 December 2023
Summary:
Sangamo Therapeutics annual selling, general & administrative expenses is currently $61.17 million, with the most recent change of -$1.51 million (-2.42%) on 31 December 2023. During the last 3 years, it has fallen by -$5.93 million (-8.84%). SGMO annual SG&A is now -8.84% below its all-time high of $67.10 million, reached on 31 December 2020.SGMO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$11.05 M
-$996.00 K-8.27%
30 September 2024
Summary:
Sangamo Therapeutics quarterly selling, general & administrative expenses is currently $11.05 million, with the most recent change of -$996.00 thousand (-8.27%) on 30 September 2024. Over the past year, it has dropped by -$2.87 million (-20.61%). SGMO quarterly SG&A is now -39.08% below its all-time high of $18.14 million, reached on 31 March 2023.SGMO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$5.83 B
-$134.84 M-2.37%
30 September 2024
Summary:
Sangamo Therapeutics TTM selling, general & administrative expenses is currently -$5.83 billion, with the most recent change of -$134.84 million (-2.37%) on 30 September 2024. Over the past year, it has dropped by -$5.90 billion (-9143.97%). SGMO TTM SG&A is now -50620.29% below its all-time high of $67.13 million, reached on 31 March 2021.SGMO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.4% | -20.6% | -9144.0% |
| 3 y3 years | -8.8% | -23.8% | -9214.9% |
| 5 y5 years | +30.9% | -25.9% | -9666.4% |
SGMO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -8.8% | at low | -39.1% | at low | -72.0% | at low |
| 5 y | 5 years | -8.8% | +30.9% | -39.1% | at low | -136.9% | at low |
| alltime | all time | -8.8% | >+9999.0% | -39.1% | +4988.9% | <-9999.0% | at low |
Sangamo Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $11.05 M(-8.3%) | $47.96 M(-5.6%) |
| June 2024 | - | $12.04 M(+2.4%) | $50.83 M(-7.2%) |
| Mar 2024 | - | $11.77 M(-10.2%) | $54.80 M(-10.4%) |
| Dec 2023 | $61.17 M(-2.4%) | $13.10 M(-5.9%) | $61.17 M(-5.2%) |
| Sept 2023 | - | $13.92 M(-13.1%) | $64.51 M(-3.5%) |
| June 2023 | - | $16.01 M(-11.7%) | $66.83 M(+1.4%) |
| Mar 2023 | - | $18.14 M(+10.3%) | $65.91 M(+5.1%) |
| Dec 2022 | $62.68 M(-0.8%) | $16.44 M(+1.3%) | $62.68 M(+0.6%) |
| Sept 2022 | - | $16.24 M(+7.6%) | $62.32 M(+2.9%) |
| June 2022 | - | $15.09 M(+1.2%) | $60.59 M(-2.2%) |
| Mar 2022 | - | $14.91 M(-7.3%) | $61.98 M(-2.0%) |
| Dec 2021 | $63.22 M(-5.8%) | $16.08 M(+10.9%) | $63.22 M(-1.2%) |
| Sept 2021 | - | $14.50 M(-12.0%) | $64.01 M(-2.6%) |
| June 2021 | - | $16.49 M(+2.1%) | $65.69 M(-2.1%) |
| Mar 2021 | - | $16.15 M(-4.3%) | $67.13 M(+0.0%) |
| Dec 2020 | $67.10 M(+8.8%) | $16.87 M(+4.3%) | $67.10 M(+2.8%) |
| Sept 2020 | - | $16.18 M(-9.8%) | $65.28 M(+2.0%) |
| June 2020 | - | $17.93 M(+11.2%) | $64.02 M(+5.5%) |
| Mar 2020 | - | $16.12 M(+7.1%) | $60.69 M(-1.6%) |
| Dec 2019 | $61.69 M(+32.0%) | $15.05 M(+0.9%) | $61.69 M(+1.1%) |
| Sept 2019 | - | $14.92 M(+2.2%) | $60.99 M(+6.9%) |
| June 2019 | - | $14.60 M(-14.7%) | $57.06 M(+6.1%) |
| Mar 2019 | - | $17.12 M(+19.2%) | $53.77 M(+15.0%) |
| Dec 2018 | $46.74 M(+71.8%) | $14.36 M(+30.6%) | $46.74 M(+17.3%) |
| Sept 2018 | - | $10.99 M(-2.7%) | $39.85 M(+13.0%) |
| June 2018 | - | $11.30 M(+12.0%) | $35.28 M(+17.5%) |
| Mar 2018 | - | $10.09 M(+35.1%) | $30.01 M(+10.3%) |
| Dec 2017 | $27.20 M(+3.3%) | $7.47 M(+16.3%) | $27.20 M(+10.6%) |
| Sept 2017 | - | $6.42 M(+6.4%) | $24.60 M(+6.0%) |
| June 2017 | - | $6.04 M(-17.0%) | $23.20 M(-17.9%) |
| Mar 2017 | - | $7.28 M(+49.6%) | $28.25 M(+7.3%) |
| Dec 2016 | $26.33 M(+37.2%) | $4.86 M(-3.2%) | $26.33 M(-0.1%) |
| Sept 2016 | - | $5.02 M(-54.7%) | $26.36 M(+1.8%) |
| June 2016 | - | $11.09 M(+107.0%) | $25.89 M(+30.6%) |
| Mar 2016 | - | $5.36 M(+9.6%) | $19.82 M(+3.3%) |
| Dec 2015 | $19.20 M(+22.5%) | $4.89 M(+7.2%) | $19.20 M(+3.0%) |
| Sept 2015 | - | $4.56 M(-9.1%) | $18.64 M(+4.7%) |
| June 2015 | - | $5.02 M(+6.0%) | $17.81 M(+6.2%) |
| Mar 2015 | - | $4.73 M(+9.3%) | $16.77 M(+6.9%) |
| Dec 2014 | $15.68 M(+13.6%) | $4.33 M(+16.1%) | $15.68 M(+0.8%) |
| Sept 2014 | - | $3.73 M(-6.1%) | $15.55 M(+3.8%) |
| June 2014 | - | $3.97 M(+9.0%) | $14.98 M(+6.0%) |
| Mar 2014 | - | $3.64 M(-13.3%) | $14.14 M(+2.4%) |
| Dec 2013 | $13.80 M(+13.6%) | $4.21 M(+32.9%) | $13.80 M(+9.4%) |
| Sept 2013 | - | $3.16 M(+1.2%) | $12.61 M(+0.2%) |
| June 2013 | - | $3.12 M(-5.6%) | $12.59 M(+3.1%) |
| Mar 2013 | - | $3.31 M(+9.6%) | $12.21 M(+0.5%) |
| Dec 2012 | $12.14 M(-13.5%) | $3.02 M(-3.8%) | $12.14 M(-1.7%) |
| Sept 2012 | - | $3.14 M(+14.4%) | $12.36 M(-3.5%) |
| June 2012 | - | $2.74 M(-15.4%) | $12.81 M(-6.8%) |
| Mar 2012 | - | $3.24 M(+0.2%) | $13.74 M(-2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $14.04 M(+11.6%) | $3.23 M(-9.9%) | $14.04 M(+0.6%) |
| Sept 2011 | - | $3.59 M(-2.3%) | $13.96 M(+5.3%) |
| June 2011 | - | $3.68 M(+3.9%) | $13.26 M(+3.3%) |
| Mar 2011 | - | $3.54 M(+12.2%) | $12.84 M(+2.0%) |
| Dec 2010 | $12.59 M(-0.2%) | $3.15 M(+9.2%) | $12.59 M(-6.1%) |
| Sept 2010 | - | $2.89 M(-11.3%) | $13.40 M(+1.4%) |
| June 2010 | - | $3.26 M(-0.9%) | $13.21 M(+1.9%) |
| Mar 2010 | - | $3.29 M(-17.3%) | $12.96 M(+2.9%) |
| Dec 2009 | $12.61 M(+22.0%) | $3.97 M(+47.0%) | $12.61 M(+15.3%) |
| Sept 2009 | - | $2.70 M(-10.2%) | $10.93 M(+1.3%) |
| June 2009 | - | $3.01 M(+2.8%) | $10.79 M(+4.5%) |
| Mar 2009 | - | $2.93 M(+27.4%) | $10.33 M(-0.0%) |
| Dec 2008 | $10.33 M(+24.3%) | $2.30 M(-10.5%) | $10.33 M(-1.7%) |
| Sept 2008 | - | $2.56 M(+0.7%) | $10.51 M(+8.6%) |
| June 2008 | - | $2.54 M(-13.1%) | $9.67 M(+4.7%) |
| Mar 2008 | - | $2.93 M(+18.5%) | $9.24 M(+11.2%) |
| Dec 2007 | $8.31 M(+17.3%) | $2.47 M(+42.9%) | $8.31 M(+6.8%) |
| Sept 2007 | - | $1.73 M(-18.2%) | $7.78 M(+2.1%) |
| June 2007 | - | $2.11 M(+5.7%) | $7.62 M(+4.0%) |
| Mar 2007 | - | $2.00 M(+2.9%) | $7.33 M(+3.4%) |
| Dec 2006 | $7.09 M(+57.1%) | $1.94 M(+23.8%) | $7.09 M(+19.1%) |
| Sept 2006 | - | $1.57 M(-13.8%) | $5.95 M(+6.3%) |
| June 2006 | - | $1.82 M(+3.8%) | $5.60 M(+11.4%) |
| Mar 2006 | - | $1.75 M(+117.5%) | $5.03 M(+11.4%) |
| Dec 2005 | $4.51 M(+6.0%) | $807.00 K(-33.6%) | $4.51 M(+4.7%) |
| Sept 2005 | - | $1.22 M(-2.7%) | $4.31 M(+0.1%) |
| June 2005 | - | $1.25 M(+0.7%) | $4.31 M(-0.3%) |
| Mar 2005 | - | $1.24 M(+105.8%) | $4.32 M(+1.5%) |
| Dec 2004 | $4.26 M(+18.4%) | $603.00 K(-50.3%) | $4.26 M(+11.1%) |
| Sept 2004 | - | $1.21 M(-3.8%) | $3.83 M(-2.6%) |
| June 2004 | - | $1.26 M(+7.0%) | $3.93 M(+2.5%) |
| Mar 2004 | - | $1.18 M(+562.4%) | $3.84 M(+6.8%) |
| Dec 2003 | $3.59 M(-13.7%) | $178.00 K(-86.5%) | $3.59 M(+7.6%) |
| Sept 2003 | - | $1.32 M(+13.0%) | $3.34 M(+6.9%) |
| June 2003 | - | $1.17 M(+24.6%) | $3.13 M(-2.2%) |
| Mar 2003 | - | $935.00 K(-1346.7%) | $3.19 M(-23.3%) |
| Dec 2002 | $4.16 M(-12.3%) | -$75.00 K(-106.8%) | $4.16 M(+3.8%) |
| Sept 2002 | - | $1.10 M(-10.8%) | $4.01 M(-17.9%) |
| June 2002 | - | $1.23 M(-35.2%) | $4.89 M(-6.1%) |
| Mar 2002 | - | $1.90 M(-942.5%) | $5.21 M(+31.9%) |
| Dec 2001 | $4.75 M(+4.0%) | -$226.00 K(-111.4%) | $3.95 M(-43.6%) |
| Sept 2001 | - | $1.98 M(+27.2%) | $7.00 M(+20.7%) |
| June 2001 | - | $1.55 M(+141.1%) | $5.80 M(+19.8%) |
| Mar 2001 | - | $644.00 K(-77.2%) | $4.84 M(-2.5%) |
| Dec 2000 | $4.57 M(+153.8%) | $2.83 M(+264.9%) | $4.96 M(+132.3%) |
| Sept 2000 | - | $775.00 K(+30.3%) | $2.14 M(+56.9%) |
| June 2000 | - | $595.00 K(-22.4%) | $1.36 M(+77.6%) |
| Mar 2000 | - | $767.00 K | $767.00 K |
| Dec 1999 | $1.80 M(+45.5%) | - | - |
| Dec 1998 | $1.24 M(+55.2%) | - | - |
| Dec 1997 | $797.00 K(+147.5%) | - | - |
| Dec 1996 | $322.00 K | - | - |
FAQ
- What is Sangamo Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual SG&A year-on-year change?
- What is Sangamo Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly SG&A year-on-year change?
- What is Sangamo Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM SG&A year-on-year change?
What is Sangamo Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of SGMO is $61.17 M
What is the all time high annual SG&A for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual selling, general & administrative expenses is $67.10 M
What is Sangamo Therapeutics annual SG&A year-on-year change?
Over the past year, SGMO annual selling, general & administrative expenses has changed by -$1.51 M (-2.42%)
What is Sangamo Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of SGMO is $11.05 M
What is the all time high quarterly SG&A for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly selling, general & administrative expenses is $18.14 M
What is Sangamo Therapeutics quarterly SG&A year-on-year change?
Over the past year, SGMO quarterly selling, general & administrative expenses has changed by -$2.87 M (-20.61%)
What is Sangamo Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of SGMO is -$5.83 B
What is the all time high TTM SG&A for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM selling, general & administrative expenses is $67.13 M
What is Sangamo Therapeutics TTM SG&A year-on-year change?
Over the past year, SGMO TTM selling, general & administrative expenses has changed by -$5.90 B (-9143.97%)